Publicaciones en colaboración con investigadoras/es de Universitat de Barcelona (17)

2022

  1. Nanoclay-reinforced HA/alginate scaffolds as cell carriers and SDF-1 delivery-platforms for bone tissue engineering

    International Journal of Pharmaceutics, Vol. 623

2020

  1. iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation

    Molecular Therapy - Methods and Clinical Development, Vol. 17, pp. 858-870

2019

  1. Enzymatic crosslinked gelatin 3D scaffolds for bone tissue engineering

    International Journal of Pharmaceutics, Vol. 562, pp. 151-161

2017

  1. Benznidazole nanoformulates: A chance to improve therapeutics for Chagas disease

    American Journal of Tropical Medicine and Hygiene, Vol. 97, Núm. 5, pp. 1469-1476

  2. Determination of the spatiotemporal dependence of Pseudomonas aeruginosa biofilm viability after treatment with NLC-colistin

    International Journal of Nanomedicine, Vol. 12, pp. 4409-4413

2016

  1. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients

    Journal of Cystic Fibrosis, Vol. 15, Núm. 5, pp. 611-618

  2. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis

    International Journal of Pharmaceutics, Vol. 498, Núm. 1-2, pp. 263-273

  3. Stability study of sodium colistimethate-loaded lipid nanoparticles

    Journal of Microencapsulation, Vol. 33, Núm. 7, pp. 636-645

2015

  1. Antibióticos nanoencapsulados en el combate contra las infecciones respiratorias por "Pseudomonas aeruginosa"

    Avances en microbiología

  2. Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: A promising approach for the treatment of defective telomerase disorders

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 91, pp. 91-102

  3. Specific requirements for somatic cell therapy medicinal products and tissue engineered products

    Pharmaceuticals Policy and Law, Vol. 17, Núm. 1-2, pp. 271-277

  4. Specific requirements regarding module 5

    Pharmaceuticals Policy and Law, Vol. 17, Núm. 1-2, pp. 279-281

2014

  1. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

    International Journal of Pharmaceutics, Vol. 477, Núm. 1-2, pp. 485-494

2009

  1. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors

    Journal of Controlled Release, Vol. 133, Núm. 1, pp. 52-59

2006

  1. PMSE 309-F MALDI TOF MS of group IVA polymers containing acyclovir

    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY

2005

  1. Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules

    Molecular Therapy, Vol. 12, Núm. 2, pp. 283-289

1985

  1. Pharmacokinetics of amoxapine and its active metabolites

    International Journal of Clinical Pharmacology, Therapy and Tox., Vol. 23, pp. 180-185